Teva is buying Montvale, NJ-based Barr Pharmaceuticals for $7.4 billion and will take on debt of $1.5 billion.
Product news
May 20, 2008
6:30 pm
Bayer HealthCare Pharmaceuticals announced that a reformulation of the liquid Leukine (sargramostim) has been approved by FDA and is now available for patients and physicians in the US.
Product news
March 25, 2008
5:00 pm
Canadian regulators have approved Novartis’ Diovan (valsartan) to treat chronic heart failure in patients who cannot tolerate angiotensin-converting-enzyme (ACE) inhibitors, a common type of heart failure therapy.
Sudler & Hennessey named global AOR for developmental arthritis med
Sudler & Hennessey (S&H) has been selected by AstraZeneca as the global agency partner of record for the developmental arthritis treatment PN400.
Product news
March 20, 2008
5:42 pm
Cephalon announced that the FDA has approved Treanda (bendamustine hydrochloride) for injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease.
Product news
March 18, 2008
4:13 pm
Hawthorn Pharmaceuticals announced the FDA approval of the company’s Granisol (granisetron HCl) oral solution. Granisol is an oral solution for the prevention of nausea and vomiting associated with cancer therapy.
Endo Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for the prescription medicine Voltaren Gel (diclofenac sodium topical gel) 1%.
Product news
March 4, 2008
7:01 pm
The FDA approved Wyeth’s Pristiq (desvenlafaxine) to treat adult patients with major depressive disorder. Wyeth expects to begin shipping Pristiq to wholesalers beginning in the second quarter of 2008.
Product news
February 28, 2008
6:00 pm
The FDA approved AstraZeneca’s Nexium (esomeprazole magnesium) for short-term use in children ages one -11 years for the treatment of gastroesophageal reflux disease (GERD).
Product news
February 26, 2008
6:00 pm
Sciele Pharma expaned its alliance with Sanofi-Aventis with a new exclusive, three-year agreement to market Allegra orally disintegrating tablets (ODT) and Allegra oral suspension in the pediatric market in the US.